News Brief
Summary
Eli Lilly becomes the first healthcare company to reach a $1 trillion market capitalization, driven by high demand for its weight loss and diabetes drugs, Zepbound and Mounjaro.
Key Points
- Eli Lilly hit $1 trillion market cap, joining an elite group dominated by tech firms.
- Stock surged over 36% this year, outperforming rival Novo Nordisk in GLP-1 drugs.
- Zepbound and Mounjaro drove massive sales growth: Mounjaro revenue up 109% to $6.52B in Q3; Zepbound sales rose 184% to $3.59B.
- Demand expected to grow with expanded approvals and insurance coverage; oral version of drugs anticipated next year.
- Weight loss drug market could exceed $150B by early 2030s; Novo Nordisk and Pfizer remain key competitors.
新闻简报
总结
礼来公司成为首家市值突破1万亿美元的医疗保健公司，主要得益于其减肥和糖尿病药物Zepbound和Mounjaro的高需求。
关键点
- 礼来公司市值达1万亿美元，加入由科技公司主导的精英俱乐部。
- 今年股价上涨超36%，在GLP-1药物领域超越竞争对手诺和诺德。
- Zepbound和Mounjaro推动销售大幅增长：Mounjaro第三季度收入增长109%至65.2亿美元；Zepbound销售额增长184%至35.9亿美元。
- 随着批准和保险覆盖范围扩大，需求预计增长；口服版本药物预计明年上市。
- 到2030年代初，减肥药市场规模可能超过1500亿美元；诺和诺德和辉瑞仍是主要竞争对手。
Original Article Link: https://www.cnbc.com/2025/11/21/eli-lilly-hits-1-trillion-market-value-first-for-health-care-company.html